hypothyroidism%20(pediatric)
HYPOTHYROIDISM (PEDIATRIC)
Hypothyroidism is due to decreased or absent production of thyroid hormone.
Primary hypothyroidism is caused by generalized tissue resistance to thyroid hormone and disorders that affect the thyroid gland directly. It is responsible for majority of hypothyroid cases.
Central hypothyroidism is caused by hypothalamic or pituitary disorders.

Principles of Therapy

  • Treatment should be started if obtained capillary thyroid stimulating hormone (TSH) concentration on neonatal screening is ≥40 mU/L & another venous blood sample has been obtained
  • Treatment may be delayed until thyroid function test results are available if the capillary TSH concentration is <40 mU/I
  • Patients w/ low venous free thyroxine (FT4) concentrations & venous thyroid stimulating hormone (TSH) concentration of >20 mU/L should receive treatment immediately
  • Transient hypothyroidism (eg subacute & drug-induced thyroiditis) should be treated during the hypothyroid phase
  • Newborns w/ elevated TSH should be treated empirically w/ thyroid hormone replacement until 2 years of age to avoid permanent cognitive deficits due to hypothyroidism
    • Treatment started w/in 2 weeks after birth increases better optimal long-term outcome

Treatment Goals

  • To restore a euthyroid state by normalizing the serum TSH
  • To improve the hypothyroid symptoms & decrease goiter size

Pharmacotherapy

Levothyroxine (T4)

  • Used as replacement therapy for hypothyroidism
  • Available in pure form, stable & inexpensive, w/ half-life of 7 days
  • Dose varies depending on the age, body weight, cardiac status, & disease severity
    • Neonates & children require larger replacement doses due to their rapid metabolism
    • Infants w/ very low total T4 or FT4 concentration prior to initiation of therapy should receive the highest initial dose
  • In most patients w/ hypothyroidism, treatment can be initiated w/ the full estimated dose requirement
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS JPOG - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
6 days ago
In patients with type 2 diabetes, obesity may be protective against vision-threatening diabetic retinopathy, a recent Korea study has shown.
Yesterday
The aromatase inhibitor anastrozole shows promise in the treatment of children with congenital adrenal hyperplasia, reducing bone age advancement without adversely affecting bone mineral density and visceral adipose tissue, as shown in a recent study.
Roshini Claire Anthony, 5 days ago

Men with metastatic hormone-sensitive prostate cancer (mHSPC) who receive testosterone suppression therapy may have a better survival outcome with the addition of enzalutamide over other non-steroidal anti-androgen (NSAA) therapies, according to the phase III ENZAMET* trial.

6 days ago
The use of opioids may have limited long-term efficacy in the management of chronic noncancer pain, reports a new study.